SPRIX

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Length of Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sprix</td>
<td>ketorolac nasal spray</td>
<td>5 days</td>
</tr>
</tbody>
</table>

Approvable Criteria:

1. Is the member 18 years of age or older?
   - If yes, continue to #2.
   - If no, do not approve.

2. Does the member have a documented contraindication to opioid/narcotic short-term pain management (must be fully described in request) such as history of abuse or true opioid allergy?
   - If yes, continue to #3.
   - If no, do not approve.

3. Is the member intolerant to oral medications, such as ketorolac tablets (intractable nausea and vomiting or swallowing disorder)?
   - If yes, approve for 5 days.
   - If no, do not approve.

QL = 5 x 30 DAYS

FDA-Approved Indication:

Indicated for short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level.

The usual dosage is 31.5 mg (one 15.75 mg spray in each nostril) every six to eight hours. The maximum daily dose is 136 mg. Sprix nasal spray should not be used for longer than five days. Longer use increases the risk of serious complications including gastrointestinal bleeding and renal injury.

References:
- Clinical Summary Documents provided by Express Scripts. Review date 5/20/11.